Abstract Aims/hypothesis: This study evaluated the hypothesis that peroxisome proliferator-activated receptor-γ (PPARγ) agonists, including thiazolidinediones (TZDs) and the rexinoid LG100268 (LG), directly affect human vascular cell function (proliferation, cell cycle, protein expression, lactate release) independently of (1) WAF-1/Cip1 and p27 Kip were differently affected in HUVECs, all agents reduced (p<0.05) expression of cyclins (D3, A, E, B), cyclin-dependent kinase-2 and hyperphosphorylated retinoblastoma protein. The rank order of the antiproliferative effects of TZDs in HUVECs (RSG≈PIO≈ RWJ<TRO) contrasted their PPRE transcriptional activities (TRO<PIO<RSG<RWJ), but correlated with cellular lactate release. Proliferation inhibition and lactate release were mimicked by rotenone (mitochondrial complex I inhibitor). Conclusions/interpretation: In conclusion, this study suggests that the antiproliferative action of the TZDs in vascular cells is independent of their PPARγ-activating and associated insulin-sensitising potential, but could relate to mitochondrial mechanisms.
Introduction
Thiazolidinediones (TZDs) improve insulin resistance in patients with type 2 diabetes [1] and are regarded to exert their metabolic effects via activation of peroxisome proliferator-activated receptor-γ (PPARγ). Recent data [2] suggest, however, that the TZDs' hypoglycaemic actions do not only relate to PPARγ activation, but also to mitochondrial mechanisms at the level of complex I of the respiratory chain, resulting in increased anaerobic glycolysis (i.e. lactate release) and loss of cellular energy charge.
By their metabolic action, TZDs can indirectly protect the vascular endothelium against metabolic damage and thus beneficially affect the development of late diabetic microvascular and macrovascular complications.
Recent experimental studies, however, suggest that TZDs and other PPARγ activators also directly affect vascular cell function by modulation of vascular cells' secretory profile [3] [4] [5] [6] [7] as well as of their proliferative [8] [9] [10] [11] [12] and inflammatory response [6, 7, 13] .
Whether such direct vascular TZD action depends on cell type (microvasculature vs macrovasculature) and PPARγ activation or relates to PPARγ-independent [14] mitochondrial [2, 15] mechanisms remains to be elucidated.
Therefore, this study tested the hypothesis that direct effects of TZDs on human vascular cell functions are independent of (1) these agents' PPARγ-activating potential and insulin-sensitising activity and (2) the cells' vascular origin. To this end, we studied the influence of the naturally occurring PPARγ-activator 15-deoxy-Δ 12,14 -prostaglandin J 2 , of LG100268, a ligand of the retinoid X receptor (RXR; which forms heterodimeric complexes with PPARγ) and of different TZDs (rosiglitazone, pioglitazone, troglitazone and RWJ241947=MCC-555 [16] ) on human fetal and adult venous and retinal endothelial cells as well as retinal pericytes to access proliferation and the associated protein expression, PPARγ-dependence and mitochondrial function.
Subjects and methods
Reagents Reagents were from Sigma (St. Louis, MO, USA) if not stated otherwise.
Cell culture Human umbilical vein endothelial cells (HUVECs), isolated and cultured as described previously [17] [18] [19] , were used as individual isolates in the first subculture.
Human adult vein endothelial cells (HAVECs) were isolated from excess superficial saphenous veins [19] , harvested for bypass procedures and cultured as described for HUVECs [17] [18] [19] . Cells were used as individual isolates in second to fifth subculture.
Human retinal endothelial cells (HRECs) and pericytes (HRPYCs): human eyes were obtained from the local eye bank within 20 h of the donor's death. Preparation and digestion of retinae were performed as described by Grant and Guay [20] . Cell suspensions were plated onto gelatin-coated culture dishes (1) in DMEM supplemented with heparin (Biochrom, Berlin, Germany; 7.5 U/ml), penicillin, streptomycin, fungizone, insulin-transferrin-selenite, VEGF (BioSource, Camarillo, CA, USA; 50 ng/ml), human serum (20%) for HREC cultures, or (2) in EGM-2 bullet medium (BioWhittaker, Verviers, Belgium) for HRPYC cultures. Subcultures were performed using trypsin-EDTA and cultures were purified using Dynabeads (Dynal, Hamburg, Germany) coated with monoclonal antibodies against CD31 (HRECs) or 3G5 cell surface ganglioside (HRPYCs), the latter collected in medium from mouse hybridoma cells CR-1814 (American Type Culture Collection, Rockville, MD, USA). Experiments were performed using individual isolates in second to fifth subculture.
Endothelial cells were identified by typical phase contrast 'cobblestone' morphology and by immunofluorescence to von Willebrand factor antigen. Pericytes were characterised by the presence of both α-and F-actin and by immunoreactivity with monoclonal antibody 3G5 [21] .
Experimental setup Primary cells were made quiescent by contact inhibition and an overnight starvation period in Medium 199 supplemented with 0.02% BSA and antibiotics. The cells were trypsinised and replated at a density of 10,000 cells/cm 2 in M199 supplemented with 5% fetal calf serum (FCS; Hyclone, Logan, UT, USA), heparin and antibiotics. After adherence (4 h), the cells were preincubated (2 h) with 2-50 μmol/l pioglitazone (PIO), troglitazone (TRO), rosiglitazone (RSG), or LG100268 (LG) (all from Sankyo, Tokyo, Japan), with RWJ241947 (RWJ) (generously provided by Johnson & Johnson, Raritan, NJ, USA), or with 15-deoxy-Δ 12, 14 -prostaglandin J 2 (PGJ 2 ), or the complex I inhibitor rotenone (ROT) vs intra-individual control cells (incubated with DMSO=solvent). After preincubation, vascular cells were stimulated to re-enter the cell cycle by addition of 10 ng/ml basic fibroblast growth factor (bFGF; Gibco, Paisley, Scotland).
After a final exposure time of 48 h to the above-mentioned agents, the cells were assayed for proliferation, cell cycle distribution, protein expression and cell numbers. Lactate release and bromodeoxyuridine (BrdU) incorporation were determined after 20 h of exposure.
Determination of proliferation Cells were exposed to the above-mentioned agents (2-50 μmol/l) vs intra-individual control cells (incubated with DMSO=solvent) in the presence of [ 3 H]thymidine (Amersham Pharmacia, Buckinghamshire, UK; 37 kBq/ml). After 48 h, cells were trypsinised, lysed, harvested and the incorporated [ 3 H]thymidine was counted as described [17, 19] . Some experiments were performed in the presence of the PPARγ antagonists BADGE and PD068235 (generously provided by Pfizer, Ann Arbor, MI, USA). Proliferation rates are given as a percentage of the respective intra-individual control cultures (set to 100%). Samples were tested in quadruplicates.
High-resolution cell cycle analysis Exposure (20 h) of HUVECs to the above-mentioned agents (2-50 μmol/l) vs intra-individual control cells (incubated with DMSO=sol-vent) was performed in the presence of bromodeoxyuridine (BrdU), applying the BrdU Flow Kit (BD PharMingen, San Diego, CA, USA) according to the manufacturer's instructions. Cells that were actively synthesising DNA (BrdU incorporation) in terms of cell cycle position (7-aminoactinomycin staining) were quantified by two parameter FACS (fluorescence activated cell sorting) analysis. BrdU incorporation determines the percentage of cells that have already passed through S phase.
Propidium iodide cell cycle analysis After incubation (48 h) with the different agents on test vs intra-individual control cells (incubated with DMSO=solvent), HUVECs and HAVECs were scraped off the dishes and fixed in ice-cold ethanol (75%). Total DNAwas stained with propidium iodide (1 μg/ml) and analysed using a FACS Calibur (Becton Dickinson, Heidelberg, Germany) as described previously [18] . Data are given as the percentage of cells residing in each cell cycle phase compared to intra-individual control cells (incubated with DMSO=solvent).
Western blot analysis After a 48-h incubation period with the agents on test vs intra-individual control cells (incubated with DMSO=solvent), HUVECs were lysed in cold Weinberg Buffer as described [17] [18] [19] . Aliquots of 10 μg total protein were subjected to SDS polyacrylamide gel electrophoresis and then transferred onto nitrocellulose membranes (Schleicher & Schüll, Kassel, Germany). Blocking of unspecific binding sites with non-fat dry milk (5% in tris-buffered saline) containing 0.05% Tween-20 (Bio Rad, Hercules, CA, USA) was followed by incubation with primary antibodies (p27 Kip pRb [Calbiochem, Cambridge, MA, USA]) and detection with horse radish peroxidase-conjugated anti-mouse or antirabbit IgG (Amersham Pharmacia, Buckinghamshire, UK; 1:2,500) using Super Signal Substrate (Pierce, Rockford, IL, USA). Western blots were exposed to Kodak XAR5-Omat films and semiquantitative evaluation of visualised bands on autoradiographies was carried out by densitometry (Gel documentation system; MWG Biotech, Ebersberg, Germany) using Gene Profiler 3.56 for Windows, over multiple exposures, to verify that readings were in the linear range. Results are expressed as differences to intra-individual control cells (incubated with DMSO=solvent, set to 100%).
Cell numbers After exposure (48 h) of HUVECs to the above-listed agents vs intra-individual control cells (incubated with DMSO=solvent), cell numbers were determined using a Beckman Coulter Counter Z2 (Krefeld, Germany). Data are expressed as cell numbers per 60-mm culture dish. Cell cycle reentry of quiescent HUVECs exposed to d RSG, e PIO and f TRO compared with c control upon bFGF-stimulation as shown by representative dot plots split in two regions (R2: HUVECs without BrdU incorporation; R3: BrdU-positive HUVECs after passage through S phase, i.e., having re-entered cell cycle). *p<0.05, **p<0.01, ***p<0.001 vs control PPRE transcriptional activity Confluent monolayers of primary HUVECs were trypsinised and seeded into 12-well culture plates (150,000 cells per well). The next day, HUVECs were transiently co-transfected (2.25 h) with a peroxisome proliferator-activated receptor responsive element (PPRE) driven firefly luciferase construct (0.8 μg/ ml; generously provided by Jörg Leers, Huddinge, Sweden; [22] ) and a Renilla luciferase construct (0.8 μg/ml; Promega, Madison, WI, USA; internal control for viability and transfection efficiency) using Lipofectamine Plus (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions (Lipofectamine: 4 μl/ml; Plus reagent 8 μl/ml) in M199. After an overnight equilibration period in full growth medium, HUVECs were exposed (20 h) to the agents to be tested vs intra-individual control cells (incubated with DMSO=solvent). After lysis (15 min, passive lysis buffer; Promega, Madison, WI, USA), the activities of both luciferases were measured by means of a dual-luciferase reporter assay system (Promega, Madison, WI, USA) using a Lumat LB 9507 luminometer (Berthod, Bad Wildbach, Germany). Results, which were standardised to Renilla luciferase activity, are expressed as a percentage of the respective intra-individual control cultures (set to 100%).
Lactate release Lactate release from HUVECs incubated (20 h) with/without the respective test agents was determined enzymatically by the lactate dehydrogenase method [23] using 200 μl cell culture supernatant. Lactate release was calculated as described [23] .
Statistics Data are expressed as means±SE. Statistical analysis was performed using paired samples t-test (SPSS for Windows7.5.1).A p value of 0.05 was considered significant.
Results

Proliferation
Macrovascular cells Proliferation of HUVECs (Fig. 1a) and HAVECs (Fig. 1b) was concentration-dependently reduced by TRO and PGJ 2 , whereas RWJ, RSG and PIO as well as the RXR ligand, LG, inhibited proliferation only at the highest concentration used compared with intraindividual control cultures exposed to DMSO (solvent). (Fig. 2a) and HRPYCs (Fig. 2b 
Microvascular cells Proliferation of HRECs
Cell cycle analyses
Cell cycle re-entry In DMSO-treated control HUVECs (n=4), 52±2% of cells passed through S phase within 20 h (Fig. 2c) , whereas the percentage of cells re-entering cell cycle upon incubation with RWJ (45±3%, p<0.05), RSG (36±5%, p<0.05; Fig. 2d ) and PIO (28±5%, p<0.01; Fig. 2e ) was markedly reduced. TRO (14±2%, p<0.001; Fig. 2f ), PGJ 2 (7±1%, p<0.01) and LG (8±2%, p<0.01) almost completely abolished the number of cells re-entering the cell cycle.
Cell cycle distribution
In HUVECs, all substances tested induced an arrest in the G 0 /G 1 phase (Fig. 3a) of the cell cycle by concomitantly reducing the number of cells residing in S phase (Fig. 3b) . Increasing the concentration of PGJ 2 to 50 μmol/l did not further augment these effects (data not shown). Only TRO and LG diminished (p<0.01) the portion of HUVECs in G 2 /M phase (not shown within figures) at the highest concentration used from 17±2% to 6.3±0.7% and 6±1%, respectively. Similar results were obtained in four individual isolates of HAVECs (data not shown).
Protein expression
In HUVECs, TZDs, PGJ 2 and LG reduced protein expression of cyclin D3 (G 1 phase cyclin; Fig. 4a) , cyclin E (G 1 /S transition; Fig. 4b ), cyclin A (S phase cyclin; Fig. 5a ) and cyclin B (G 2 /M phase; Fig. 5b ) and the cyclin-dependent kinase cdk-2 (forming complexes with the cyclins D3, E and A; Fig. 6a ). In parallel, hyperphosphorylation of the retinoblastoma protein (pRb) was markedly reduced (Fig. 6b) , whereas a hypophosphorylated band appeared in cells exposed to TZDs, PGJ 2 and LG (Fig. 7a, autoradiographies) .
In HUVECs (n=5), protein expression of the inhibitor of cyclin-dependent kinases (CKI) p27
Kip was exclusively affected by PGJ 2 (at 25 μmol/l: −59±14%, p<0.01), whereas that of p21 WAF-1/Cip1 (another CKI) was increased by RWJ (at 50 μmol/l: +137±48%, p<0.05), but reduced by the other agents being tested (at 50 μmol/l: RSG: −46±13%, p<0.05; 
PPRE transcriptional activity
In HUVECs, 10 μmol/l of TZDs as well as of the natural PPARγ ligand PGJ 2 increased PPRE transcriptional activity (Fig. 7b) . Incubation with 50 μmol/l TZDs and 25 μmol/l PGJ 2 did not further increase PPRE activation (data not shown). Addition of 200 nmol/l of either PPARγ antagonist, BADGE and PD068235, inhibited PGJ 2 -induced PPRE transcriptional activity by 39±7% and by 58± 6% respectively in two individual HUVEC isolates.
Lactate release
TZDs as well as rotenone, a specific inhibitor of complex I of the respiratory chain, increased the rates of lactate release from HUVECs ( Fig. 8a) and concomitantly reduced proliferation. In HUVECs, incubated with PGJ 2 and LG, inhibition of proliferation did not correlate with lactate release (Fig. 8b, white squares) . In endothelial cells exposed to rotenone (r=−0.998, p<0.01; Fig. 8b , black line) and TZDs (at 25 μmol/l: r=−0.981, p<0.01, data not shown within figure; at 50 μmol/l: r=−0.989, p<0.001; Fig. 8b , dotted line), however, proliferation inversely correlated with lactate release.
Discussion
The antiproliferative activities of different PPARγ-agonists including four thiazolidinediones (TRO, RSG, PIO, RWJ), the naturally occurring ligand 15-deoxy-Δ 12,14 -prostaglandin J 2 and a RXR-ligand (LG) were evaluated in human macrovascular cells (HUVECs, HAVECs) and microvascular retinal cells (HRECs and HRPYCs) with respect to cell type specificity and PPARγ dependence.
All the PPARγ-agonists tested reduced proliferation in all the cell types studied (HUVECs, HAVECs, HRECs, HRPYCs), as has also recently been shown for smooth muscle cells [24] . The naturally occurring ligand PGJ 2 , the RXR-ligand LG and the thiazolidinedione TRO showed the highest antiproliferative activities, whereas RSG, PIO and RWJ displayed smaller, but comparable potencies with respect to inhibition of proliferation. Compared with HUVECs, HAVECs and HRPYCs, we observed an attenuated antiproliferative activity in human retinal endothelial cells (HREC), especially in response to TRO and LG. Thus, the individual TZD's antiproliferative activity seems to depend on both the respective agent and the specific vascular origin.
The antiproliferative activities of the PPARγ/RXR agonists observed in human endothelial cells relate to inhibition of the cells' transition from the G 0 /G 1 phase to the S phase of the cell cycle, mirrored by the cells' accumulation in G 0 /G 1 phase. HUVECs exposed to PPARγ/RXR ligands show diminished cell cycle re-entry as determined by high-resolution cell cycle analyses, being in line with the associated reduction of cyclin D3 expression, which is rate-limiting for S-phase entry [25, 26] .
In HUVECs, TZDs, PGJ 2 and LG reduced expression of cdk-2 (which forms active complexes with the cyclins D3, E and A) and prevented phosphorylation of pRb, as mirrored by reduction of hyperphosphorylated pRb and appearance of its hypophosphorylated form [27] . Hyperphosphorylated pRb releases the transcription factor E2F, which, in its free form, induces transcription of cyclins as well as of several DNA replication enzymes [28, 29] , whereas hypophosphorylated pRb binds E2F [30] and thus inhibits cell cycle progression by repressing induction of cell cycle regulatory molecules. TZD-induced reduction of cyclin E (S-phase cyclin) and A (G 2 /M-phase cyclin) thus reflect reduction of hyperphosphorylated pRb and induction of hypophosphorylated pRb, both resulting in cell cycle arrest. Similar mechanisms (e.g. reduced hyperphosphorylation of pRb) of the TZDs' antiproliferative actions were previously reported for cultured smooth muscle cells [24, 31] .
Protein expression of p27 Kip was not affected by TZDs or by LG in HUVECs, suggesting that this inhibitor of cyclin-dependent kinases is of minor importance in endothelial cells' G 0 /G 1 cell cycle arrest induced by PPARγ/ RXR ligands.
Protein expression of p21 WAF-1/Cip1 was diminished in HUVECs exposed to PIO, RSG, TRO and PGJ 2 , but was increased by RWJ. At first glance, the observation of high vs reduced p21 WAF-1/Cip1 expression, both going along with reduced endothelial proliferation, seems contradictory. It has previously been shown, however, that threshold levels of p21 WAF-1/Cip1 are necessary for assembly of cyclin-cdk complexes [32] and thus also for cell cycle progression in response to growth factors or mitogens. Indeed, reduced mitogenic stimulation of p21 WAF-1/Cip1 by RSG and TRO has already been found associated with reduced proliferation in rat aortic smooth muscle cells [31] . On the other hand, upregulation of p21 WAF-1/Cip1 protein is known to actively repress cell cycle progression by inhibiting the activity of cyclin-dependent kinases [27, 32] . Thus, as observed in the present study, notably both reduced mitogenic stimulation as well as active upregulation of p21 WAF-1/Cip1 lead to the same downstream event, i.e. hypophosphorylation of pRb and, as a consequence, to reduced proliferation.
Since the insulin-sensitising efficacy of TZDs parallels their PPARγ activating potency, it has been assumed that the vascular effects of TZDs also depend on this mechanism [33, 34] . Recent studies in skeletal muscle [2] , however, suggested that mitochondrial mechanisms, independently of PPARγ activation, could also account for the effects of TZDs.
We show that the rank order of the TZDs' PPRE transcriptional activities (TRO<PIO<RSG<RWJ), reflecting the described PPARγ activating potencies of these substances [16, 35] , clearly differs from the rank order of the TZDs' antiproliferative effects in HUVECs (RSG≈ PIO≈RWJ< TRO). Based on these data we suggest that the underlying mechanisms of the TZDs' antiproliferative effects are independent of PPARγ activation. Such hypothesis is corroborated by our findings that the antiproliferative effects of TZDs in HUVECs were not counteracted by the PPARγ inhibitors BADGE and PD068235, although both agents reduced PGJ 2 -induced PPRE transcriptional activity.
In vitro, in various cell types, TZDs have been shown to inhibit cell respiration and to increase lactate release [36, 37] . This effect has been attributed to immediate and PPARγ-independent inhibition of complex I of the respiratory chain [2] and was suggested as a common mechanism contributing to the TZDs' hypoglycaemic actions [2] . Thus, we evaluated the effects of different PPARγ ligands, including TZDs, on lactate release as an indicator of mitochondrial function in human vascular endothelial cells. In HUVECs exposed to TZDs (but not to LG and PGJ 2 ) proliferation (expressed as cells per 60-mm dish) inversely correlated with the cells' lactate release, indicating impaired mitochondrial function. Our experiments with the specific complex I inhibitor, rotenone, suggest that inhibition of cell respiration, putatively by inhibition of complex I, could mediate the observed antiproliferative action of TZDs. Thus, the TZDs' ability to modulate mitochondrial function obviously not onlyrelates to skeletal muscle [2] , canine kidney cells [36] and rat astrocytes [37] , but also to human vascular endothelial cells.
In cultured endothelial cells, oxidised LDL has been reported to increase the activity of mitochondrial complex I [38] , which is speculated to be the major source of superoxide anions and ROS (reactive oxygen species) in vivo [39] . Increased oxidative stress, mediated by the proatherogenic diabetic milieu, was previously shown to induce endothelial cell dysfunction [40, 41] preceding diabetic microangiopathy and macroangiopathy. By direct modulation of endothelial cell mitochondrial function, proliferation and ROS production [39] , TZDs could beneficially affect diabetes-associated vascular complications.
The concentrations of TZDs used in this study (2, 10, 25 and 50 μmol/l) were comparable to those used in similar experimental studies [8, 9, 11, 12, 42] and are (1) within the peak plasma concentrations (≈5 μmol/l) achieved in patients after daily oral administration of 4 mg RSG, 30 mg PIO, or 400 mg TRO [43] [44] [45] ; or (2) within the pharmaco-logical range (25 and 50 μmol/l). Vascular cells exposed to these concentrations of TZDs were fully viable (as tested by trypan blue exclusion; data not shown).
In conclusion, our data demonstrate that thiazolidinediones exert antiproliferative activity in all types of vascular cells studied. Such data are of importance, since vascular injury, induced by a proatherogenic diabetic milieu [46] [47] [48] , is characterised by accelerated proliferation of vascular cells (including endothelial and smooth muscle cells) preceding the manifestation of both macrovascular and microvascular complications (e.g. proliferative retinopathy, atherosclerosis). The observed direct antiproliferative actions of thiazolidinediones in vascular cells (1) seem to be independent of PPARγ activation and thus from their reported insulin-sensitising potential, but (2) correlate with lactate release, possibly due to inhibition of mitochondrial function on the level of complex I.
